CV1: ESTIMATING THE IMPACT OF ANTICOAGULATION QUALITY ON EVENT RATES  by Matchar, PB & Samsa, GP
 Abstracts
 
403
 
METHODS:
 
 Data on mucositis and clinical parameters
of hospitalization, IV antibiotic use, fever, analgesic use,
and parenteral nutrition were collected as part of a multi-
center clinical trial conducted in Europe (n  234). Pa-
tients were quantified as having mucositis if ulcerative
lesions were present after receiving BEAM (BCNU, Eto-
poside, Ara-C, Melphalan) HDC. Days of usage for clini-
cal parameters were quantified as resource consumption
and compared in patients with and without mucositis.
RESULTS: Mucositis showed an association with resource
consumption. Days of analgesia had the highest correla-
tion followed by antibiotic use, fever, hospitalization, and
parenteral nutrition (r  0.4128*, 0.3003*, 0.2634*,
0.2558*, 0.0973, respectively, *p  .0001). Patients with
mucositis had two additional days of hospitalization and
three additional days of IV antibiotics. Mean  s.e. for re-
source consumption is listed for patients (with mucositis,
without mucositis, p-value), as follows: days of hospital-
ization (26.8  0.4, 24.4  0.5, p  .001); days of IV an-
tibiotics (12.6  0.7, 9.5  0.7, p  .002); days of anal-
gesic use (9.2  0.7, 4.3  0.5, p  .001); days of
parenteral nutrition (1.8  0.3, 1.6  0.2, p  .668);
days of fever (2.9  0.3, 2.0  0.3, p  .035).
CONCLUSIONS: Patients with mucositis had signifi-
cantly higher resource consumption. Mucositis impacts
on length of hospitalization, days of fever, IV antibiotic,
and analgesic use.
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OBJECTIVES:
 
 The majority of patients with non-small
cell lung cancer (NSCLC) present with advanced disease,
for which pharmacological therapy is the primary treat-
ment option. Economic models are useful tools to help
decision-makers determine the cost and health impact of
existing and new therapies in their practice settings.
METHODS: A decision-analytic model was developed to
represent the progression of advanced (stage IIIB/IV)
NSCLC from diagnosis and first-line therapy to subse-
quent lines of therapy, best supportive care and death.
The model is a semi-Markov process with three-week cy-
cles and a two-year time horizon. By selecting different
sets of model parameters, it may be used to estimate cost-
of-illness (by pooling cost and health outcomes across a
range of therapies), cost-effectiveness (comparison be-
tween new or existing therapeutic options) and impact on
health-care budgets. Data sources include published clini-
cal trials, treatment patterns based on published studies,
and a panel of US clinicians and US unit costs. In this
case, the NSCLC model was used to examine the costs
and outcomes of a distribution of mono and combination
agents most commonly administered as first and second-
line therapy in the US.
RESULTS: Over one and two years respectively the aver-
age cost of therapy was $42,319 and $48,151 per pa-
tient, with an estimated survival of 40.2% and 7.4%.
The estimated cost for a health-care purchaser with a
prevalence of 100 patients with advanced NSCLC was
$4.90 million per year. If all patients used carboplatin
and paclitaxel as first-line therapy, this increased to
$5.14 million. If a new therapy increased the median time
to progression for patients on first-line therapy by two
months, the cost increased to $5.0 million per year.
CONCLUSION: This model provides a flexible analyti-
cal platform for a range of economic evaluations of alter-
native therapeutic strategies in advanced NSCLC. This is
valuable for strategic planning in Phase II/III drug devel-
opment.
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ESTIMATING THE IMPACT OF 
ANTICOAGULATION QUALITY
ON EVENT RATES
Matchar DB, Samsa GP
Duke University, Durham, NC, USA
OBJECTIVES: Warfarin anticoagulation has been shown
to effectively decrease the rate of thromboembolism (TE),
with an associated increased rate of bleeding. Maximiz-
ing the benefit and minimizing the risk depends on main-
taining patients in a narrow therapeutic range for pro-
thrombin time (measured as INR). An increased percentage
of time spent in target range (TTR) is predictive of better
clinical outcomes. However, strategies to increase TTR can
be costly. To allow local clinical policy makers to deter-
mine whether these strategies can be justified, we developed
a general approach to estimating bleeding and TE rates as-
sociated with a given population distribution of INR.
METHODS: We used data from a large cohort (Cannegi-
eter, 1995) to derive a logistic equation for baseline abso-
lute risk of bleeding as a function of INR. Based on a sep-
arate large cohort of patients (Fihn, 1993) with various
times since initiation of therapy, we derived a risk ratio
that modifies the above baseline relationship that ac-
counts for time since initiation of therapy. A similar strat-
egy was used to estimate TE, using INR and indication
(mechanical valve versus atrial fibrillation) as predictors.
RESULTS: The model for bleeding was: logit(p)  8.84 
0.83 INR  0.64 EARLY, where EARLY  1 if the pa-
tient is in the first 3 months of anticoagulation, and 0
otherwise. The final model for TE was: logit(p)  0.73
1.17 INR  0.64(AF), where AF  1 if the indication is
atrial fibrillation and 0 if the indication is mechanical
heart valve. The integral of these logistic equations,
weighted by a given population distribution of INR, pro-
vides population estimates of annual bleed and TE rates.
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CONCLUSION: Existing epidemiological data can pro-
vide tailored estimates of concrete benefits resulting from
improving the quality of anticoagulation.
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A SIX YEAR FOLLOW-UP STUDY OF THE 
RELATIONSHIP BETWEEN MORTALITY, 
HOSPITALISATION AND ADHERENCE TO 
STATIN TREATMENT AFTER FIRST 
MYOCARDIAL INFARCTION
Wei L, Wang J, Davey P, MacDonald T
MEMO, University of Dundee, Dundee, UK
OBJECTIVE: To measure adherence to statins by pa-
tients treated for secondary prevention after myocardial
infarction and to estimate the effect of adherence on out-
come.
METHODS: We used a cohort design in the population
of Tayside, Scotland. Patients who experienced their first
MI between January 1990 and November 1995 were
identified from hospital discharge data. We used two out-
comes: mortality from any cause; hospitalization for re-
current MI. Adherence to statins was calculated as the
number of days for which statins were supplied divided
by the total number of days in the study for each patient.
Results were adjusted for age, sex, deprivation (as mea-
sured by the Carstairs code), serum cholesterol level, dia-
betes mellitus, cardiovascular drugs and other hospital-
ization using a Cox regression model.
RESULTS: Of 5590 patients enrolled in the cohort 1299
(23.2%) died during the follow-up period and 717
(12.8%) experienced at least one further MI. Only 7.7%
of patients used statins, and in comparison with non-us-
ers, these patients had more cardiovascular risk factors.
Compared to those not using statins, the adjusted relative
risk of mortality (95% CI) by quintiles of adherence was
0.65 (0.24–1.80) for the worst adherence quintile, 0.46
(0.06–3.43) for the second, 1.03 (0.37–2.88) for the
third, 0.19 (0.03–1.37) for the fourth, and 0.20 (0.09–
0.47) for the best adherence quintile. The adjusted rela-
tive risks of readmission by quintiles of adherence were
0.65 (0.24–1.79) for the worst adherence quintile, 0.47
(0.06–3.51) for the second, 1.05 (0.37–2.94) for the
third, 0.20 (0.03–1.41) for the fourth, and 0.21 (0.09–
0.48) for the best adherence quintile.
CONCLUSIONS: Statins were used infrequently and use
was a marker of cardiovascular risk. Despite such confound-
ing by indication, good adherence to treatment was associ-
ated with lower risks of further MI and lower mortality.
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VASOPEPTIDASE INHIBITOR REDUCES
IN-HOSPITAL COSTS FOR CONGESTIVE
HEART FAILURE PATIENTS: RESULTS
FROM THE IMPRESS TRIAL
Eisenstein EL1, Nelson CL1, Simon TA2, Smitten AL3, Lapuerta 
P2, Mark DB1
1Duke Clinical Research Institute, Durham, NC, USA; 2Bristol-
Myers Squibb, Princeton, NJ, USA; 3Yale University School of 
Medicine, New Haven, CT, USA
OBJECTIVE: The IMPRESS clinical trial randomized pa-
tients with congestive heart failure to a daily regimen of
either omapatrilat or lisinopril. At 24 weeks, patients
randomized to omapatrilat had a significant reduction in
the primary endpoint of death, hospitalization, or discon-
tinuation of study drug for worsening heart failure (p 
.035) and fewer cardiac events (p  .04). This study
sought to determine the economic consequences of the
omapatrilat patient’s lower event rates.
METHODS: Economic outcomes were assessed in terms
of hospitalization events and their medical costs. Hospi-
tal event information was obtained via serious adverse
event forms, and hospital costs were evaluated by assign-
ing each hospitalization a DRG-based average cost for
physician and hospital services. Emergency room visits
for worsening heart failure were assigned costs equivalent
to those at Duke University Medical Center. All costs
were expressed in 1998 US dollars. Drug costs were not
assessed.
RESULTS: Patients in the omapatrilat (n  289) and lisi-
nopril (n  284) arms were evenly matched with regard
to baseline characteristics: age (both 64 years); NYHA
class III or IV heart failure (36% versus 38%); ejection
fraction (both 28%). There was no difference between study
arms in all-cause mortality. However, there was a trend to-
ward a greater number of all-cause hospitalizations in
the lisinopril versus omapatrilat patients (0.275 versus
0.215, p  .07). Differences in cardiac hospitalizations be-
tween lisinopril and omapatrilat were significant (0.208
versus 0.145, p  .03). There was a trend toward re-
duced medical costs at 24 weeks follow-up in omapatri-
lat-treated patients (US$1930 versus US$2002, p  .09).
Considering only cardiac medical costs, this trend toward
reduced medical costs became significant (US$1240 ver-
sus US$1442, p  .03).
CONCLUSIONS: In the first study to compare economic
outcomes in congestive heart failure patients treated with
omapatrilat and lisinopril, we found fewer hospitaliza-
tions and lower medical costs for omapatrilat patients at
24 weeks.
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IMPACT OF CENSORED COST DATA ON THE 
OUTCOMES OF ECONOMIC EVALUATIONS
Oostenbrink JB, Al MJ, Rutten-van Mölken MM
Institute for Medical Technology Assessment, Rotterdam, 
Netherlands
OBJECTIVE: Patients in a clinical trial who withdraw
before the scheduled end date are a serious problem in
economic evaluations. The method to deal with data
from these patients can have important impact on out-
